News & Events
- Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
- Publication of interim report Q3 2025
- Genetic Analysis AS announces milestone in the IBD diagnostic test development project – completion of biomarker panel for GA-map® IBD Precision Dx
- Genetic Analysis AS announces milestone in the IBD diagnostic test development project - completion of biomarker panel for GA-map® IBD Precision Dx
- Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
- Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
- Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
- Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
- Genetic Analysis attends the Biomarkers & Precision Medicine congress in London
- Genetic Analysis AS launches the GA-map® MHI GutHealth reagent kit
- Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
- Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
- Publication of Half-year report 2025
- Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Genetic Analysis AS and Pangea Laboratory LLC announces the launch of GA-map® MHI GutHealth in the USA